On July 24, ZAI LAB fell 5.05% in regular trading, trading at 15.24 HKD/share, with turnover of approximately 53.04 million HKD.

The decline was driven by a confluence of investment bank downgrades and broader sector weakness. JPMorgan recently slashed its target price on ZAI LAB from $39 to $32, following earlier cuts by Morgan Stanley to 19 HKD and BOCI to 17 HKD for the Hong Kong-listed shares. The successive downgrades reflect concerns over weaker-than-expected first-quarter revenue, which fell 6% year-on-year to $99.6 million, with net losses widening to $51 million. Analysts noted that declining sales of key products Zejula and the impact of medical insurance price negotiations on Vyvgart weighed on near-term growth prospects.

The broader Biotechnology sector also traded under pressure, amplifying the selloff. Among sector peers, AKESO fell 4.09%, 3SBIO declined 2.79%, INNOVENT BIO dropped 2.53%, and SKB BIO lost 1.73%, while BEIGENE bucked the trend with a 2.06% gain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)